前列欣胶囊联合特拉唑嗪治疗前列腺增生症的临床研究  

Clinical study of Qianliexin Capsules combined with terazosin in treatment of benign prostatic hyperplasia

作　　者：赵小顺[1] 都军[2] 陈红利[3] 王新丽[4] ZHAO Xiao-shun;DU Jun;CHEN Hong-li;WANG Xin-li(Department of Pharmacy,Xinxiang Central Hospital,Xinxiang 453000,China;Department of Urology,Xinxiang Central Hospital,Xinxiang 453000,China;Department of Clinical Pharmacy,Xinxiang Central Hospital,Xinxiang 453000,China)

机构地区：[1]新乡市中心医院药学部,河南新乡453000 [2]新乡市中心医院泌尿外二科,河南新乡453000 [3]新乡市中心医院临床药学科,河南新乡453000 [4]新乡市中心医院泌尿外科,河南新乡453000

出　　处：《现代药物与临床》2020年第11期2216-2219,共4页Drugs & Clinic

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20191317)。

摘　　要：目的探讨前列欣胶囊联合盐酸特拉唑嗪胶囊治疗前列腺增生症的临床疗效。方法选取2018年5月—2020年5月在新乡市中心医院治疗的前列腺增生症患者242例,根据用药的差别分为对照组(121例)和治疗组(121例)。对照组口服盐酸特拉唑嗪胶囊,2 mg/次,1次/d;治疗组在对照组基础上口服前列欣胶囊,3.0 g/次,3次/d。两组患者均治疗30 d。观察两组患者临床疗效,同时比较治疗前后两组患者前列腺体积、残余尿量(PVR)、最大尿流率(Qmax),IPSS、VSS、QOL和USPSS评分,及血清胰岛素样生长因子-1(IGF-1)、B细胞淋巴瘤/白血病-2(Bcl-2)、脂蛋白相关磷脂酶A2(LP-PLA2)和白细胞介素-17(IL-17)水平。结果治疗后,对照组临床总有效率为80.49%,显著低于治疗组的97.56%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者前列腺体积、PVR均显著降低(P<0.05),而Qmax均显著升高(P<0.05),且治疗组明显好于对照组(P<0.05)。治疗后,两组患者IPSS评分、VSS评分、QOL评分、USPSS评分均显著下降(P<0.05),且治疗组下降最为明显(P<0.05)。治疗后,两组患者血清IGF-1、Bcl-2、Lp-PLA2、IL-17水平均明显降低(P<0.05),且治疗组明显低于对照组(P<0.05)。结论前列欣胶囊联合盐酸特拉唑嗪胶囊治疗前列腺增生症可有效改善患者临床症状,降低血清IGF-1、Bcl-2、Lp-PLA2、IL-17水平,提高患者生活质量,具有一定的临床推广应用价值。Objective To investigate the clinical efficacy of Qianliexin Capsules combined with terazosin in treatment of benign prostatic hyperplasia.Methods Patients(242 cases)with benign prostatic hyperplasia in Xinxiang Central Hospital from May 2018 to May 2020 were divided into control(121 cases)and treatment(121 cases)groups based on different treatments.Patients in the control group were po administered with Terazosin Hydrochloride Capsules,2 mg/time,once daily.Patients in the treatment group were po administered with Qianliexin Capsules on the basis of the control group,3 g/time,three times daily.Patients in two groups were treated for 30 d.After treatment,the clinical efficacy was evaluated,and the prostate volume,PVR,Qmax,and the scores of IPSS,VSS,QOL and USPSS,and the serum levels of IGF-1,Bcl-2,LP-PLA2 and IL-17 in two groups before and after treatment were compared.Results After treatment,the clinical efficacy in the control group was 80.49%,which was significantly lower than 97.56%in the treatment group,and there were differences between two groups(P<0.05).After treatment,the prostate volume and PVR in two groups were significantly decreased(P<0.05),but the Qmax level in two groups was significantly increased(P<0.05),and the indexes in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the scores of IPSS,VSS,QOL and USPSS in two groups were significantly decreased(P<0.05),and these scores in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,the serum levels of IGF-1,Bcl-2,LP-PLA2,and IL-17 in two groups were significantly decreased(P<0.05),and which in the treatment group were significantly lower than those in the control group(P<0.05).Conclusion Qianliexin Capsules combined with terazosin in treatment of benign prostatic hyperplasia can effectively improve the clinical symptoms,reduce the serum levels of IGF-1,Bcl-2,Lp-PLA2,and IL-17,and improve the quality of life of patients,which has a certain clinical ap

关 键 词：前列欣胶囊 盐酸特拉唑嗪胶囊 前列腺增生症 最大尿流率 胰岛素样生长因子-1 脂蛋白相关磷脂酶A2 

分 类 号：R983[医药卫生—药品]